NextCure (NXTC) Stock Price, News & Analysis

Company Overview

NextCure, Inc. is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large‐scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.

The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation. Lead programs such as NX-1607, an oral small molecule inhibitor targeting the CD200 checkpoint, and NX-0255, a monoclonal antibody directed against KIR3DL2, are being developed for solid tumors and hematologic malignancies. NextCure is also advancing NX-5948, an oral Bruton’s tyrosine kinase (BTK) degrader, into studies for B-cell malignancies. Strategic partnerships with global pharmaceutical companies support NextCure’s efforts to expand its research capabilities and accelerate clinical programs across oncology and immunology indications.

Founded in 2013 and headquartered in Beltsville, Maryland, NextCure operates state‐of‐the‐art research and development facilities in the greater Washington, D.C. area. The company conducts clinical trials across North America and Europe, collaborating with leading academic institutions and healthcare centers. By combining novel target discovery with rigorous translational and clinical research, NextCure seeks to bring new immunotherapeutic options to patients worldwide.

Key Stats

• Today's Range: $6.02 to $6.51
• 50-Day Range: $6.07 to $12.77
• 52-Week Range: $4.60 to $15.74
• Volume: 4,345 shs
• Average Volume: 43,697 shs
• Market Capitalization: $23.24 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $23.00
• Consensus Rating: Hold

NextCure Stock Analysis - MarketRank™

NextCure scored higher than 75% of companies evaluated by MarketBeat, and ranked 192nd out of 871 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Hold

Consensus Rating

NextCure has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 2 sell ratings.

Upside Potential

NextCure has a consensus price target of $23.00, representing about 257.2% upside from its current price of $6.44.

Amount of Analyst Coverage

NextCure has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for NextCure are expected to decrease in the coming year, from ($7.91) to ($9.78) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of NextCure is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of NextCure is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

NextCure has a P/B Ratio of 0.87. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.82% of the float of NextCure has been sold short.

Short Interest Ratio / Days to Cover

NextCure has a short interest ratio ("days to cover") of 1.75, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in NextCure has recently decreased by 19.58%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

NextCure does not currently pay a dividend.

Dividend Growth

NextCure does not have a long track record of dividend growth.

News and Social Media

• Score: 4.3 / 5
• News Sentiment: 0.94

News Sentiment

NextCure has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.81 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for NextCure this week, compared to 1 article on an average week.

Search Interest

1 people have searched for NXTC on MarketBeat in the last 30 days.

MarketBeat Follows

1 people have added NextCure to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.9 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, NextCure insiders have not sold or bought any company stock.

Percentage Held by Insiders

11.90% of the stock of NextCure is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

42.65% of the stock of NextCure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/07/2026
• Today: 5/29/2026
• Next Earnings (Estimated): 8/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:NXTC
• CIK: 1661059
• Web: www.nextcure.com
• Phone: (240) 399-4900
• Fax: N/A
• Employees: 90
• Year Founded: 2015

Price Target and Rating

• Average Price Target for NextCure: $23.00
• High Price Target: $36.00
• Low Price Target: $15.00
• Potential Upside/Downside: +257.2%
• Consensus Rating: Hold
• Rating Score (0-4): 2.20
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($17.19)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$55.84 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -186.96%
• Return on Assets: -124.62%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.61
• Quick Ratio: 4.61

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.40 per share
• Price / Book: 0.87

Miscellaneous

• Outstanding Shares: 3,610,000
• Free Float: 3,182,000
• Market Cap: $23.24 million
• Optionable: No Data
• Beta: 1.43